CountryOfPapers CountryOfPapers
Journal list Promote
verified COP 5,2 · Q1 • database Scopus / SJR & Web of Science indexed
Molecular Cancer Therapeutics
United States · American Association for Can...
workspace_premium Q1 — Cancer Research lock Subscription

Molecular Cancer Therapeutics

Molecular Cancer Therapeutics is a journal indexed in SJR in Oncology and Cancer Research with an H index of 206. It has a price of 3000 €. It has a COP Index of 5,2 (best band Q1). It is published in English. It has a COP Index of 5,2.

Molecular Cancer Therapeutics focuses its scope in these topics and keywords: inhibitor, cancer, potent, protein, cells, resistance, activity, vitro, inhibition, kinase, ...

Publisher: American Association for Cancer Research Inc.
Category: Oncology
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
COP Index trending_up
5,2 Q1

40 of 195 journals in Cancer Research

H-index · SJR 206 · 2,493
Acceptance rate pie_chart
20% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
3.000 € Subscription
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

COP Index

5,2

Q1

SJR Impact

2,493

H-index

206

Docs (year)

149

Docs 3y

518

Total refs

7085

Cites 3y

2980

Citable 3y

510

Cites/Doc 2y

4.96

Ref/Doc

47.55

Immediate OA

3000 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

FAQs